ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Fluticasone

Also written as “Fluticasone Propionate”, “Fluticasone propionate” and “Fluticasone Propionate/Formoterol Fumarate”.

Its studies are mostly in Asthma · Pulmonary Disease, Chronic Obstructive · Rhinitis, Allergic, Seasonal · Rhinitis, Allergic · Rhinitis, Allergic, Perennial, led by 24 companies.

Drug pageFluticasone: every studyMany companies study it; this page follows only the 150 they lead. All 340 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 1, 2005150 company-led studies, 5 open or runningNext primary completion: Dec 2026 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKlineits history only580 open or runningphase 4since Feb 1, 2005Feb 1, 2005none ahead
Respirent Pharmaceuticals182 open or runningphase 3since Sep 17, 2018Sep 17, 2018none ahead
Teva Pharmaceutical Industriesits history only140 open or runningphase 4since Dec 11, 2020Nov 22, 2011none ahead
Viatrisits history only130 open or runningphase 4since Dec 16, 2016Nov 21, 2006none ahead
Optinose USits history only101 open or runningphase 3since Jun 13, 2012Jun 13, 2012Mar 31, 2028phase 3 · NCT06850805
Mundipharmaits history only60 open or runningphase 4since Jun 15, 2015Oct 14, 2009none ahead
SkyePharmaits history only50 open or runningphase 3since Oct 27, 2006Oct 27, 2006none ahead
Eurofarma Laboratoriosits history only31 open or runningphase 3since Sep 14, 2010Sep 14, 2010Aug 2028phase 3 · NCT06234345
Merckits history only30 open or runningphase 2since Oct 5, 2006Oct 5, 2006none ahead
Hikma Pharmaceuticalsits history only20 open or runningno phasesince Jan 5, 2016Jan 5, 2016none ahead

Also a collaborator on its studies: Paratek Pharmaceuticals, Becro, Prolytic, Dynamic Solutions, Parexel, Vectura and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Respirent Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Sep 17, 2018.

  1. Nov 15, 2018Phase 1 study in BioequivalenceNCT03751202 · 34 enrolled · Greece
  2. Jan 25, 2019Phase 1 study in BioequivalenceNCT03820180 · 34 enrolled · Greece
  3. Mar 26, 2019Phase 1 study in BioequivalenceNCT03894280 · 36 enrolled · Greece
  4. Jun 3, 2019Phase 1 study in BioequivalenceNCT03975166 · 34 enrolled · Greece
  5. Jul 5, 20202 phase 1 studies in BioequivalenceNCT04462822, NCT04466176
  6. Sep 6, 20202 phase 1 studies in BioequivalenceNCT04546256, NCT04564456
  7. Dec 7, 2020Phase 3 study in AsthmaNCT04665895 · 451 enrolled · Greece
  8. Feb 8, 2021Phase 1 study in AsthmaNCT04746040 · 50 enrolled · Greece
  9. Aug 19, 2021Phase 1 study in AsthmaNCT05021887 · 50 enrolled · Greece
  10. Oct 8, 2021Phase 1 study in AsthmaNCT05085587 · 18 enrolled · Greece
  11. May 25, 2022Phase 1 study in AsthmaNCT05397834 · 36 enrolled · Greece
  12. Dec 15, 2022Phase 3 study in AsthmaNCT05664061 · 451 enrolled · Greece
  13. Jan 10, 2023Phase 1 study in BioequivalenceNCT05697003 · 34 enrolled · Greece
  14. Aug 1, 20232 phase 1 studies in BioequivalenceNCT05982990, NCT06025214

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 18 Respirent Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06025214Bioequivalence · Greece1RecruitingSep 22, 202334
NCT05982990Bioequivalence · Greece1Active, not recruitingSep 1, 202334
NCT05697003Bioequivalence · Greece1UNKNOWNMar 31, 202334
NCT05664061Asthma · Greece3UNKNOWNJul 31, 2023451
NCT05397834Asthma · Greece1UNKNOWNJun 21, 202236
NCT05085587Asthma · Greece1UNKNOWNOct 25, 202118
NCT05021887Asthma · Greece1UNKNOWNSep 30, 202150
NCT04746040Asthma · Greece1UNKNOWNFeb 25, 202150
NCT04665895Asthma · Greece3CompletedAug 13, 2021451
NCT04564456Bioequivalence · Greece1CompletedOct 31, 202034
NCT04546256Bioequivalence · Greece1CompletedSep 25, 202014
NCT04466176Bioequivalence · Greece1CompletedAug 4, 202034
NCT04462822Bioequivalence · Greece1CompletedSep 9, 202014
NCT03975166Bioequivalence · Greece1CompletedJun 25, 201934
NCT03894280Bioequivalence · Greece1CompletedApr 9, 201936
NCT03820180Bioequivalence · Greece1CompletedFeb 12, 201934
NCT03751202Bioequivalence · Greece1CompletedDec 11, 201834
NCT03676413Asthma · Greece3CompletedAug 2, 2019451

How it is read

Names in the registry

  • “Fluticasone Propionate”, 17 entries
  • “Fluticasone propionate”, 13 entries
  • “Fluticasone Propionate/Formoterol Fumarate”, 9 entries
  • “fluticasone propionate”, 7 entries
  • “fluticasone propionate/salmeterol”, 7 entries

Codes read as this program: NCX4251, FP100.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.